申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04616014A1
公开(公告)日:1986-10-07
New triazine derivatives represented by the formula: ##STR1## wherein R.sup.1 is aryl, pyridyl, thienyl, 1,2,3,4-tetrahydroquinolyl or 1,3,4,5-tetrahydro-2H-1-benzazepinyl, optionally substituted with lower alkyl, lower alkoxy, halogen, nitro or oxo, R.sup.2 is hydrogen, lower alkyl or carbamoyl substituted with lower alkyl or ar(lower)alkyl, and Z is a group selected from ##STR2## and pharmaceutically acceptable salt thereof, processes for preparation thereof and pharmaceutical compositions comprising the same of antihypertensive and antithrombotic activity.
新的三嗪衍生物的化学式如下:##STR1## 其中 R.sup.1 是芳基、吡啶基、噻吩基、1,2,3,4-四氢喹啉基或1,3,4,5-四氢-2H-1-苯并氮杂环基,可选择地取代为较低的烷基、较低的烷氧基、卤素、硝基或氧代基,R.sup.2 是氢、较低的烷基或羰胺基,其被较低的烷基或芳基(烷基)取代,Z 是从##STR2## 中选择的基团及其药学上可接受的盐,以及制备这些化合物的方法和包含具有抗高血压和抗血栓活性的相同药物组合物。